TAK - Takeda Pharmaceutical Company Limited
| Previous Close | 16.09 |
| Open | 15.99 |
| Bid | 16.11 x 3200 |
| Ask | 16.12 x 3200 |
| Day's Range | 16.00 - 16.12 |
| 52 Week Range | 12.28 - 17.15 |
| Volume | |
| Avg. Volume | 2,295,009 |
| Market Cap | 51.216B |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | 22.38 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.66 (4.10%) |
| Ex-Dividend Date | Sept 29, 2022 |
| 1y Target Est | N/A |
- Zacks
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now
Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.
- Reuters
LATAM POLITICS TODAY-Lawyers for Peruvian ex-president Toledo try to block extradition
Lawyers for Peru's former President Alejandro Toledo filed for an emergency stay in a U.S. federal court on Thursday to block his extradition to the South American country, where he faces corruption charges. The lawyers argued in their early morning filing that a stay of his detention and extradition was "necessary to avoid imminent and irreparable harm of an erroneous deprivation of liberty, and possibly also life" if he is extradited by the Friday deadline set by a judge in California. The Pan American Health Organization (PAHO) is in preliminary talks with Japanese drugmaker Takeda over potential orders of its dengue vaccine, PAHO's director said on Thursday, though it has yet to decide whether it will recommend the shot.
- Zacks
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Motley Fool
2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now
High-yield dividend stocks can be a great way to protect your portfolio from market volatility. Read on to find out more about these two high-yield dividend stocks. Ford, and most of its contemporaries, took a big step backward last year over concerns about the impact of rising interest rates on demand for new vehicles.
- Zacks
Is Grifols (GRFS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Motley Fool
Is This the Telltale Sign to Sell Novavax Stock?
Unfortunately, Novavax (NASDAQ: NVAX) hasn't had great timing. The company was late to the party in winning authorizations for its COVID-19 vaccine, Nuvaxovid. If you only looked at Novavax's press releases, you wouldn't know about some recent bad news for the company.
- Reuters
Japan's Takeda's profit slips 13%, pipeline bolsters outlook
Japan's Takeda Pharmaceutical Co posted a 13% drop in operating earnings for the nine months ended December but kept its profit outlook for the fiscal year unchanged as it works to bolster its drugs pipeline. Takeda's annual operating profit forecast of 530 billion yen already lags a Refinitiv analysts' consensus forecast of 593.9 billion yen. European Union regulators in December approved Takeda's vaccine for dengue fever, branded as QDENGA.
- Reuters
Slumping China-bound Japanese exports raise fears of global downturn
Japan's export growth slowed sharply in December as China-bound shipments fell for the first time in seven months, stoking fears of further slowdown in the global economy and external demand for Japanese shipments. Exports rose 11.5% year-on-year in December after a gain of 20% in November, marking the slowest growth since the start of 2022, dragged down by a fall-off in sales to China of cars, auto parts and chip-making machinery, Ministry of Finance (MOF) data showed on Thursday. Exports to largest trading partner China fell 6.2% year-on-year in value and were down 24% in volume terms in December.
- Reuters
UPDATE 2-Japan's Takeda to buy Nimbus' psoriasis drug for as much as $6 bln
Takeda Pharmaceutical will buy U.S.-based Nimbus Therapeutics' experimental psoriasis drug for up to $6 billion, the Japanese drugmaker said on Tuesday, as it looks to cut reliance on treatments facing loss of patents. The drug, codenamed "NDI-034858", last week showed statistically significant reduction in moderate-to-severe psoriasis in a mid-stage study and is expected to enter late-stage trials next year. The company is also studying the drug to treat inflammatory bowel disease and psoriatic arthritis.
- Reuters
UPDATE 3-Japan's Takeda secures EU nod for its dengue vaccine
A dengue vaccine developed by Japanese drugmaker Takeda Pharmaceutical Co was authorised for use in the European Union on Thursday, making it the second approved inoculation against the mosquito-borne disease that causes millions of infections annually. The vaccine, branded QDENGA, is authorized for use in those aged 4 and older to prevent any of the four so-called serotypes of dengue. Between 20,000 and 25,000 people, mostly children, die each year from the virus, according to the World Health Organization.
- Motley Fool
Why Puma Biotechnology's Shares Jumped 20% on Monday
The biopharmaceutical company specializes in cancer therapies. Its stock got a boost on Monday when a Takeda Pharmaceutical (NYSE: TAK) candidate, ponatinib, hit its primary goal in a phase 3 clinical trial as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia. The blood cancer therapy works by slowing the activity of BCR-ABL1, a gene sequence found in an abnormal chromosome 22, often seen in people with certain types of leukemia.
- Motley Fool
2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade
Are these a couple of rare opportunities that investors shouldn't pass up, or are the price drops valid because of significant concerns that should keep you away from these companies? Takeda is a Japan-based healthcare company that makes vaccines and pharmaceutical products.
- Motley Fool
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
One happy consequence of a bear market is that dividend yields rise as stock prices fall. Three beaten-up stocks trading near their 52-week lows that could be especially attractive right now include Takeda Pharmaceuticals (NYSE: TAK), Duke Energy (NYSE: DUK), and Home Depot (NYSE: HD). Japanese drugmaker Takeda Pharmaceuticals is a leading healthcare company that makes vaccines and products addressing multiple therapeutic areas, including cancer, rare diseases, gastroenterology, and hematology.
- Zacks
TAK vs. ZTS: Which Stock Should Value Investors Buy Now?
TAK vs. ZTS: Which Stock Is the Better Value Option?
- Zacks
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.
- Zacks
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Motley Fool
Got $5,000? These 2 Dividend Stocks Haven't Been This Cheap in Years
When dividend stocks dip in price and go on sale, they can create buying opportunities for long-term investors. Takeda Pharmaceuticals (NYSE: TAK) and Verizon Communications (NYSE: VZ) are both at multi-year lows, and here's why they could be attractive options for a $5,000 investment. Takeda Pharmaceuticals is one of the largest drug companies in the world.
- Zacks
TAK or ZTS: Which Is the Better Value Stock Right Now?
TAK vs. ZTS: Which Stock Is the Better Value Option?
- Zacks
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks
TAK vs. ZTS: Which Stock Is the Better Value Option?
TAK vs. ZTS: Which Stock Is the Better Value Option?
- Thomson Reuters StreetEvents
Edited Transcript of 7733.T earnings conference call or presentation 9-Aug-22 10:59am GMT
Q1 2023 Olympus Corp Earnings Presentation
- Zacks
Wall Street Analysts See a 26% Upside in Takeda Pharmaceutical Co. (TAK): Can the Stock Really Move This High?
The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Reuters
Takeda maintains annual guidance despite first-quarter profit drop
TOKYO (Reuters) -Japan's biggest drugmaker Takeda Pharmaceutical Co reported a sharp drop in first-quarter profit on Thursday, reflecting one-off gains a year earlier, while maintaining annual earnings forecasts that are buoyed by the yen's decline. In the first quarter of last fiscal year, Takeda benefited from a one-time gain of 131.4 billion yen when it sold off its diabetes assets to refocus on core businesses following its acquisition of Shire Plc. The next major driver for Takeda's earnings and shares may be a decision by European regulators, expected later this year, on the company's experimental vaccine for Dengue fever.
- Reuters
UPDATE 2-Takeda maintains annual guidance despite first-quarter profit drop
Japan's biggest drugmaker Takeda Pharmaceutical Co reported a sharp drop in first-quarter profit on Thursday, reflecting one-off gains a year earlier, while maintaining annual earnings forecasts that are buoyed by the yen's decline. In the first quarter of last fiscal year, Takeda benefited from a one-time gain of 131.4 billion yen when it sold off its diabetes assets to refocus on core businesses following its acquisition of Shire Plc. The next major driver for Takeda's earnings and shares may be a decision by European regulators, expected later this year, on the company's experimental vaccine for Dengue fever.
